TOOTH BRUSHING, LIFESTYLE BEHAVIORS, AND THE RISK OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Abstract Background: The monocyte/high-density lipoprotein cholesterol (HDL-C) ratio (MHR) may be a novel inflammatory marker of the developing atherosclerotic cardiovascular disease (ASCVD). We investigated the relationship between the average number of days of fish intake per week and the MHR and lifestyle behaviors and to explore the validity of stratifying the risk of ASCVD using the combination of MHR and the serum HDL-C level.Methods: This cross-sectional study was conducted in a population of 2485 males aged over 50 years at the Health Planning Center of Nihon University Hospital between April 2018 and March 2019.Results: The average frequency of fish intake was 2.32 ± 1.31 per week. Multiple stepwise regression analysis identified increased weekly fish frequency intake as an independent determinant of a decreased MHR (β = -0.072, p < 0.0001). Healthier lifestyle behaviors were also significantly associated with decreased MHR. As the fish intake frequency increased, the proportion of subjects with the cigarette smoking habit decreased (p = 0.014), that of subjects with aerobic exercise habit increased (p < 0.0001), and that of subjects with alcohol drinking habit increased (p < 0.0001). A risk stratification or ASCVD by combining the HDL-C level and fish intake frequency with the MHR could be developed, indicating that even with similar HDL-C levels, higher HMR and fish frequency are associated with higher risk ASCVD. Conclusion: A high fish intake frequency may be associated with healthier lifestyle behaviors as well as a lower MHR, and may thus represent a component of a healthy lifestyle associated with a lower risk of ASCVD in Japanese males aged over 50 years. These associations may be related to being the preventive effect of fish intake on ASCVD.Clinical Trial Registration: UMIN (http://www.umin.ac.jp/) Study ID: UMIN 000041368 registered 10/08/2020

Download Full-text

Race/Ethnic and Sex Differences in the Association of Atherosclerotic Cardiovascular Disease Risk and Healthy Lifestyle Behaviors

Journal of the American Heart Association ◽

10.1161/jaha.117.008250 ◽

2018 ◽

Vol 7 (10) ◽

Cited By ~ 8

Author(s):

Alanna A. Morris ◽

Yi‐An Ko ◽

Sarah H. Hutcheson ◽

Arshed Quyyumi

Keyword(s):

Cardiovascular Disease ◽

Sex Differences ◽

Healthy Lifestyle ◽

Disease Risk ◽

Cardiovascular Disease Risk ◽

Atherosclerotic Cardiovascular Disease ◽

Lifestyle Behaviors ◽

Healthy Lifestyle Behaviors ◽

Atherosclerotic Cardiovascular Disease Risk

Download Full-text

Faculty Opinions recommendation of Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727737949.793535337 ◽

2017 ◽

Author(s):

Alex Hoischen

Keyword(s):

Cardiovascular Disease ◽

Atherosclerotic Cardiovascular Disease ◽

Clonal Hematopoiesis

Download Full-text

Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications

Current Medicinal Chemistry ◽

10.2174/0929867324666170608103140 ◽

2018 ◽

Vol 25 (13) ◽

pp. 1480-1500 ◽

Cited By ~ 7

Author(s):

Sho-ichi Yamagishi ◽

Takanori Matsui

Keyword(s):

Cardiovascular Disease ◽

Pigment Epithelium ◽

Retinal Pigment ◽

Visceral Obesity ◽

Retinal Pigment Epithelial Cells ◽

Atherosclerotic Cardiovascular Disease ◽

Cardiometabolic Diseases ◽

The Metabolic Syndrome ◽

Pigment Epithelium Derived Factor ◽

Cardiometabolic Disorders

Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors, serpins. It was first identified as a neuronal differentiating factor secreted by human retinal pigment epithelial cells, and then found to be the most potent inhibitor of pathological angiogenesis in mammalian eyes. Recently, PEDF has been shown not only to suppress oxidative stress and inflammatory reactions in vascular wall cells, T cells and macrophages, and adipocytes, but also to exert antithrombotic and anti-fibrotic properties, thereby protecting against the development and progression of various cardiometabolic diseases and related complications. Furthermore, accumulating evidence has suggested that circulating PEDF levels may be a biomarker of severity and prognosis of these devastating disorders. Number of subjects with visceral obesity and insulin resistance is increasing, and the metabolic syndrome and its related complications, such as diabetes, nonalcoholic fatty liver disease/non-alcoholic steatohepatits, and atherosclerotic cardiovascular disease are a growing health challenge. Therefore, in this study, we review the pathophysiological role of PEDF in obesity and metabolic disorders, cardiovascular disease, diabetic eye and kidney complications, liver diseases, and reproductive system disorders, and discuss the potential clinical utility of modulating the expression and actions of PEDF for preventing these cardiometabolic disorders. We also refer to the clinical value of PEDF as a biomarker in cardiometabolic complications.

Download Full-text